Skip to main content
ASMB
NASDAQ Life Sciences

Assembly Biosciences Expands ABI-6250 Clinical Program into Cholestatic Liver Diseases, Targeting Phase 2 in Q1 2027

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$26.92
Mkt Cap
$421.154M
52W Low
$13.13
52W High
$39.705
52W Position info
105% above low
Off High info
32% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ASMB has more than doubled off its 52-week low of $13.13.

Summary

Assembly Biosciences is expanding its ABI-6250 clinical program into cholestatic liver diseases, including Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). A Phase 2 study for these new indications is anticipated to start in Q1 2027. This move significantly broadens the potential market for ABI-6250, particularly in PSC where no approved treatments currently exist, addressing a substantial unmet medical need. The company recently held a constructive pre-IND meeting with the FDA regarding this expansion. This pipeline development adds long-term value following recent Q1 results that showed a widened net loss.

At the time of this announcement, ASMB was trading at $26.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $421.2M. The 52-week trading range was $13.13 to $39.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ASMB - Latest Insights

ASMB
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.95
Real-time Price: $21.50 info
Change: +$1.55 (+8%) info
Market Cap: $432.479M info
ASMB
Nov 12, 2026, 4:00 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $20.19
Real-time Price: $21.50 info
Change: +$1.31 (+6%) info
Market Cap: $432.479M info
ASMB
Oct 05, 2026, 10:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.79
Real-time Price: $21.50 info
Change: -$1.29 (-6%) info
Market Cap: $432.479M info
ASMB
Sep 08, 2026, 4:49 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $36.00
Real-time Price: $21.50 info
Change: -$14.50 (-40%) info
Market Cap: $432.479M info
ASMB
Aug 13, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.95
Real-time Price: $21.50 info
Change: -$8.45 (-28%) info
Market Cap: $432.479M info